Skip to main navigation
Loading
  • News
  • Investors
  • Careers
  • Contact
  • About Us
    • Our Mission & Vision
    • The Zevra Story
    • Leadership
    • Board of Directors
    • What We Do
    • Partnering
  • Patients & Caregiver
    • Clinical Trials
    • Expanded Access Policy
    • Niemann-Pick Disease Type C
    • Urea Cycle Disorders
    • Vascular Ehlers-Danlos
  • Our Products
    • MIPLYFFA®
    • OLPRUVA ®
  • Our Pipeline
    • Pipeline
    • Clinical Trials
    • Publications & Presentations
    • Medical Literature
    • Medical Information
    • Investigator-Initiated Studies
  • Investors
    • Investor Relations
    • Events & Presentations
    • Stock Quote & Chart
    • Press Releases
    • Corporate Governance
    • SEC Filings
    • Contact
    • Email Alerts
  • Careers
    • Culture
    • Job Openings
  • Contact
    • info@zevra.com
    • 888.958.1253
    • Facebook
    • Twitter
    • LinkedIn
  • Home
  • Menu Menu

SEC Filings

  • Overview
  • Events & Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historic Stock Lookup
    • Analyst Coverage
  • Press Releases
  • Corporate Governance
    • Leadership
    • Board of Directors
    • Committee Composition
    • IRS – Required Disclosures
  • State Compliance
  • SEC Filings
  • Contact
  • Email Alerts
  • FAQs
Filing date Form Description Filing Group View
03-27-2026 SCHEDULE 13G/A SCHEDULE 13G/A - Description
Other
0000102909-26-002639.rtf
0000102909-26-002639.xls
0000102909-26-002639.pdf
View HTML
03-26-2026 4 Statement of changes in beneficial ownership of securities
3,4,5
0001612084-26-000002.rtf
0001612084-26-000002.xls
0001612084-26-000002.pdf
View HTML
03-19-2026 3 Initial filing by director officer or owner of more than ten percent
3,4,5
0001466562-26-000005.rtf
0001466562-26-000005.xls
0001466562-26-000005.pdf
View HTML
03-19-2026 4 Statement of changes in beneficial ownership of securities
3,4,5
0001466562-26-000007.rtf
0001466562-26-000007.xls
0001466562-26-000007.pdf
View HTML
03-16-2026 8-K Report of unscheduled material events or corporate event
Current Reports
0001434647-26-000015.rtf
0001434647-26-000015.xls
0001434647-26-000015.pdf
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
03-16-2026 144 Filed by "insiders" prior intended sale of restricted stock.
Other
0001950047-26-002681.rtf
0001950047-26-002681.xls
0001950047-26-002681.pdf
View HTML
03-09-2026 8-K Report of unscheduled material events or corporate event
Current Reports
0001434647-26-000009.rtf
0001434647-26-000009.xls
0001434647-26-000009.pdf
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
03-09-2026 10-K Annual report which provides a comprehensive overview of the company for the past year
Annual Filings
0001434647-26-000011.rtf
0001434647-26-000011.xls
0001434647-26-000011.pdf
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
03-09-2026 S-8 Securities offered to employees pursuant to employee benefit plans
Registration Statements
0001434647-26-000013.rtf
0001434647-26-000013.xls
0001434647-26-000013.pdf
XML - XBRL INSTANCE DOCUMENT View HTML
02-10-2026 4 Statement of changes in beneficial ownership of securities
3,4,5
0001681098-26-000004.rtf
0001681098-26-000004.xls
0001681098-26-000004.pdf
View HTML
Pagination
  • Current page 1
  • Page 2
  • Page 3
  • …
  • Next page ›
  • Last page »

Data provided by Kaleidoscope.

  • About Us
    • Our Mission & Vision
    • The Zevra Story
    • Leadership
    • Board of Directors
    • What We Do
    • Partnering
  • Patients & Caregiver
    • Clinical Trials
    • Expanded Access Policy
    • Niemann-Pick Disease Type C
    • Urea Cycle Disorders
    • Vascular Ehlers-Danlos
  • Our Products
    • MIPLYFFA®
    • OLPRUVA ®
  • Our Pipeline
    • Pipeline
    • Clinical Trials
    • Publications & Presentations
    • Medical Literature
    • Medical Information
    • Investigator-Initiated Studies
  • Investors
    • Investor Relations
    • Events & Presentations
    • Stock Quote & Chart
    • Press Releases
    • Corporate Governance
    • SEC Filings
    • Contact
    • Email Alerts
  • Careers
    • Culture
    • Job Openings
  • Contact
    • info@zevra.com
    • 888.958.1253
    • Facebook
    • Twitter
    • LinkedIn
  • Home

© 2026 Zevra Therapeutics, Inc. All rights reserved. Privacy Policy | Terms of Use

Scroll to top